Disposition of 25132 shares by Forgrowth Nap B.v. of NewAmsterdam Pharma at 25.4904 subject to Rule 16b-3
| NAMS Stock | 25.94 0.02 0.08% |
Slightly above 53% of NewAmsterdam Pharma's investor base is interested to short. The analysis of the overall investor sentiment regarding NewAmsterdam Pharma suggests that many traders are impartial. NewAmsterdam Pharma's investing sentiment can be driven by a variety of factors including economic data, NewAmsterdam Pharma's earnings reports, geopolitical events, and overall market trends.
NewAmsterdam |
Filed transaction by NewAmsterdam Pharma 10 Percent Owner. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
NewAmsterdam Pharma Fundamental Analysis
We analyze NewAmsterdam Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewAmsterdam Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewAmsterdam Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
NewAmsterdam Pharma is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
NewAmsterdam Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NewAmsterdam Pharma stock to make a market-neutral strategy. Peer analysis of NewAmsterdam Pharma could also be used in its relative valuation, which is a method of valuing NewAmsterdam Pharma by comparing valuation metrics with similar companies.
Peers
NewAmsterdam Pharma Related Equities
| CMPX | Compass Therapeutics | 11.43 | ||||
| ANEB | Anebulo Pharmaceuticals | 4.43 | ||||
| MLYS | Mineralys Therapeutics, | 4.08 | ||||
| CRNX | Crinetics Pharmaceuticals | 3.10 | ||||
| MOLN | Molecular Partners | 2.53 | ||||
| CGEM | Cullinan Oncology | 2.34 | ||||
| MRUS | Merus BV | 2.03 | ||||
| RZLT | Rezolute | 1.75 | ||||
| PEPG | PepGen | 1.59 | ||||
| JANX | Janux Therapeutics | 1.28 | ||||
| IVA | Inventiva | 0.93 | ||||
| GLUE | Monte Rosa | 0.84 | ||||
| REPL | Replimune | 0.48 | ||||
| PRTC | PureTech Health | 3.49 |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.